Genmab A/S GMAB
Regular-session close
After hours · Nov 20, 7:56 PM ET
- YTD
- +64.29%
- 1 year
- +68.44%
Held by funds
41 US ETFs and mutual funds hold GMAB · largest positions
- IBB 2.06% of fund $221.19M
- FBT 4.57% of fund $135.85M
- AVDE 0.14% of fund $26.67M
- CANC 6.47% of fund $12.79M
- FTQI 0.37% of fund $3.58M
- LOEV 3.50% of fund $2.99M
- JHMD 0.28% of fund $2.74M
- FNCMX 0.01% of fund $2.15M
- RBIN 0.36% of fund $1.58M
- ONEQ 0.01% of fund $1.37M
- APIE 0.13% of fund $1.33M
- AADR 3.73% of fund $1.18M
- FFTY 2.09% of fund $1.05M
- AVIV 0.05% of fund $965.33K
- AVDEX 0.11% of fund $952.01K
- CNCR 3.42% of fund $917.78K
- DFAI 0.00% of fund $778.82K
- NTSI 0.16% of fund $757.30K
- HRTS 1.02% of fund $563.62K
- DFIV 0.00% of fund $498.49K
Ownership
- Institutions 22.2%
- Insiders 0.00%
- Public and other holders 77.8%
Top institutional holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Darwin Global Management, Ltd. | 2.87% | 17,899,876 | 905.73M | Sep 29, 2026 |
| Paradigm Biocapital Advisors LP | 2.27% | 14,136,472 | 715.31M | Sep 29, 2026 |
| Orbis Allan Gray Ltd | 1.69% | 10,567,391 | 534.71M | Sep 29, 2026 |
| Deerfield Management Company, L.P | 1.10% | 6,865,000 | 347.37M | Sep 29, 2026 |
| Alliancebernstein L.P. | 1.03% | 6,403,228 | 324.00M | Sep 29, 2026 |
| Arrowstreet Capital, Limited Partnership | 0.97% | 6,069,276 | 307.11M | Sep 29, 2026 |
Top mutual fund holders
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Biotechnology ETF | 0.69% | 4,322,251 | 218.71M | Sep 29, 2026 |
| First TRT Exch-Trd Fd.-First TRT NYSE Arca Biotechnology Index Fd. | 0.50% | 3,121,944 | 157.97M | Sep 29, 2026 |
| NEW PERSPECTIVE FUND | 0.49% | 3,078,594 | 155.78M | Sep 29, 2026 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Fund | 0.08% | 520,700 | 26.35M | Jul 30, 2026 |
| American Century ETF Trust-Avantis International Equity ETF | 0.08% | 500,718 | 25.34M | Sep 29, 2026 |
| Federated Hermes Equity Funds-Federated Hermes Kaufmann Small Cap Fund | 0.06% | 350,000 | 17.71M | Jul 30, 2026 |
Included in Plus and up
Sign in to see Institutional ownership
How much funds own from their 13F filings, quarter by quarter, and the largest holders.
Free with an account
Sign in to see Insider activity
Two years of insider buying and selling by month, marked on the price.
Included in Plus and up
Sign in to see Congress trading
Every stock trade disclosed by members of the US Senate and House.
Leadership team
Who runs GMAB, and what each was last paid
Jan van de Winkel, Co-Founder, President & Chief Executive OfficerAverage age 55
| Name | Title | Pay | Age |
|---|---|---|---|
| Jan van de Winkel | Co-Founder, President & Chief Executive Officer | 3.30M DKK | 65 |
| Rayne Waller | Executive Vice President & Chief Technical Operations Officer | 1.80M DKK | 58 |
| Gregory David Emil Mueller | Executive VP, General Counsel & Chief Legal Officer | 1.70M DKK | 55 |
| Judith V. Klimovsky | Executive Vice President & Chief Development Officer | 1.30M DKK | 68 |
| Tahamtan Ahmadi | Executive Vice President, Chief Medical Officer & Head of Experimental Medicines | 1.30M DKK | 53 |
| Anthony Pagano | Executive Vice President & Chief Financial Officer | 1.10M DKK | 48 |
| Martine J. van Vugt | Executive Vice President & Chief Strategy Officer | 900K DKK | 55 |
| Christopher Cozic | Executive Vice President & Chief People Officer | 800K DKK | 48 |
| Martin Schultz | Senior Director, Head of Development Business Partnership & Strategy and Director | 300K DKK | 51 |
| Mijke Zachariasse | Vice President, Head of Antibody Research Materials & Director | 300K DKK | 53 |
Pay is the latest total FMP has for each person (salary, bonus, stock and other awards) and can lag the newest proxy statement. Source: Financial Modeling Prep, from the company’s SEC filings.
Free with an account
Sign in to see CEO compensation
What the chief executive was paid each year, by salary, bonus and stock, beside the company's earnings.
Free with an account
Sign in to see Board of directors
Who sits on the board, who chairs it, and how long each director has served.
Insiders
No insider holdings on record
